Combinations
First Claim
Patent Images
1. A combination comprising an alpha-2-delta ligand and an AChE inhibitor or a pharmaceutically acceptable salt or solvate of either thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred ACHE inhibitors are donepezil (Aricept®), tacrine (cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil.
69 Citations
14 Claims
- 1. A combination comprising an alpha-2-delta ligand and an AChE inhibitor or a pharmaceutically acceptable salt or solvate of either thereof.
- 8. A method for the curative, prophylactic or palliative treatment of pain, comprising simuHaneous, sequential or separate administration of a therapeutically effective amount of an alpha-2delta ligand and an AchE inhibitor, or pharmaceutically acceptable salt thereof, to a a mammal in need of said treatment.
-
10. A combination comprising gabapentin, or a pharmaceutically acceptable salt thereof, and a AChE inhibitor selected from donepezil (Aricept®
- ), tacrine (cognex®
), rivastigmine (Exelon®
), physostgmine (Synapton®
), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin), icopezil, hupazine A, zanapezil (TAK
147), stacofylline, phenserine, (5R,9R)-5-(r-chloro-2-hydroxy-3-methoxybenzylidene-amino)-11-ethlidene-7-methyl-1,2,5,6,9,10-hexahydro-5,methanocycloocta[b]pyridin-2-one (ZT
1), the galantamine derivatives SPH 1371, SPH 1373 and SPH 1375, tolserine, 1-(3-fluorobenzyl)-4-[(2-fluoro-5,6-dimethoxy-1-indanone-2-yl)methyl]piperidine hydrochloride (ER
127528), thiatolserine, (−
)-12-amino-3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinoline hydrochloride (huperine X), N,N-dimethylcarbamic acid 4-[1 (S)-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester hemifumarate (RS
1259), ipidacrine (Amiridin), velnacrine (Mentane®
), eptastigmine (heptylphysostigmine), zifrosilone (2,2,2-trifluoro-1-[3-(trimethylsilyl)phenyl]ethanone), 2-[2-(1-benzylpiperidin-4-yl)ethyl]-2,3-dihydro-9-methoxy-1H-pyrrolo[3,4-b]quinolin-1-one hemifumerate (T
82), 1,3-dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]-quinazoline (CI
1002), N-heptylcarbamic acid 2,4a,9-trimethyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-b]indol-6-yl ester-L-tartrate (CHF
2060), 3-(2-[1-(1,3-dioxolan-2-ylmethyl)piperidin-4-yl]ethyl)-3,4-dihydro-2H-1,3-benzoxazine-2,4-dione hydrochloride (E
2030), N-[10-(diethylamino)decyl]carbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester (MF
247), 5-amino-6-chloro-4-hydroxy-3,4-dihydro-1H-thiopyrano-[3,4-b]quinoline (MF
8615), N-[8-(cis-2,6-dimethylmorpholin-4-yl)octyl]carbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester L-bitartrate hydrate (MF
268), (−
)N-(3-piperidinopropyl)-N-demethylgalantamine (SPH
1286) and N-propargyl-3R-aminoindan-5-yl-ethyl methyl carbamate (TV
3326), or a pharmaceutically acceptable salt thereof. - View Dependent Claims (11)
- ), tacrine (cognex®
-
12. A combination comprising pregabalin and a AChE inhibitor selected from donepezil (Aricept®
- ), tacrine (cognex®
), rivastigmine (Exelon®
), physostgmine (Synapton®
), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin), icopezil, hupazine A, zanapezil (TAK
147), stacofylline, phenserine, (5R,9R)-5-(r-chloro-2-hydroxy-3-methoxybenzylidene-amino)-11-ethlidene-7-methyl-1,2,5,6,9,10-hexahydro-5,9-methanocycloocta[b]pyridin-2-one (ZT
1), the galantamine derivatives SPH 1371, SPH 1373 and SPH 1375, tolserine, 1-(3-fluorobenzyl)-4-[(2-fluoro-5,6-dimethoxy-1-indanone-2-yl)methyl]piperidine hydrochloride (ER
127528), thiatolserine, (−
)-12-amino-3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11 methanocycloocta[b]quinoline hydrochloride (huperine X), N,N-dimethylcarbamic acid 4-[1(S)-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester hemifumarate (RS
1259), ipidacrine (Amiridin), velnacrine (Mentane®
), eptastigmine (heptylphysostigmine), zifrosilone (2,2,2-trifluoro-1-[3-(trimethylsilyl)phenyl]ethanone), 2-[2-(1-benzylpiperidin-4-yl)ethyl]-2,3-dihydro-9-methoxy-1H-pyrrolo[3,4-b]quinolin-1-one hemifumerate (T
82), 1,3-dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]-quinazoline (CI
1002), N-heptylcarbamic acid 2,4a,9-trimethyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-b]indol-6-yl ester-L-tartrate (CHF
2060), 3-(2-[1-(1,3-dioxolan-2-ylmethyl)piperidin-4-yl]ethyl)-3,4-dihydro-2H-1,3-benzoxazine-2,4-dione hydrochloride (E
2030), N-[10-(diethylamino)decyl]carbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester (MF
247), 5-amino-6-chloro-4-hydroxy-3,4-dihydro-1H-thiopyrano-[3,4-b]quinoline (MF
8615), N-[8-(cis-2,6-dimethylmorpholin-4-yl)octyl]carbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester L-bitartrate hydrate (MF
268), (−
)N-(3-piperidinopropyl)-N-demethylgalantamine (SPH
1286) and N-propargyl-3R-aminoindan-5-yl-ethyl methyl carbamate (TV
3326), or a pharmaceutically acceptable salt thereof. - View Dependent Claims (13)
- ), tacrine (cognex®
-
14. A pharmaceutical composition for the curative, prophylactic or palliative treatment of pain, comprising an alpha-2-delta ligand selected from pregabalin or gabapentin and a AChE inhibitor selected from donepezil (Aricept®
- ), tacrine (cognex®
), rivastigmine (Exelon®
), physostgmine (Synapton®
), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin), icopezil, hupazine A, zanapezil (TAK
147), stacofylline, phenserine, (5R,9R)-5-(r-chloro-2-hydroxy-3-methoxybenzylidene-amino)-11-ethlidene-7-methyl-1,2,5,6,9,10-hexahydro-5,9-methanocycloocta[b]pyridin-2-one (ZT
1), the galantamine derivatives SPH 1371, SPH 1373 and SPH 1375, tolserine, 1-(3-fluorobenzyl)-4-[(2-fluoro-5,6-dimethoxy-1-indanone-2-yl)methyl]piperidine hydrochloride (ER
127528), thiatolserine, (−
)-12-amino-3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinoline hydrochloride (huperine X), N,N-dimethylcarbamic acid 4-[1 (S)-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl ester hemifumarate (RS
1259), ipidacrine (Amiridin), velnacrine (Mentane®
), eptastigmine (heptylphysostigmine), zifrosilone (2,2,2-trifluoro-1-[3-(trimethylsilyl)phenyl]ethanone), 2-[2-(1 benzylpiperidin-4-yl)ethyl]-2,3-dihydro-9-methoxy-1H-pyrrolo[3,4-b]quinolin-1-one hemifumerate (T
82), 1,3-dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]-quinazoline (CI
1002), N-heptylcarbamic acid 2,4a,9-trimethyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-b]indol-6-yl ester-L-tartrate (CHF
2060), 3-(2-[1-(1,3-dioxolan-2-ylmethyl)piperidin-4-yl]ethyl)-3,4-dihydro-2H-1,3-benzoxazine-2,4-dione hydrochloride (E
2030), N-[10-(diethylamino)decyl]carbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester (MF
247), 5-amino-6-chloro-4-hydroxy-3,4-dihydro-1H-thiopyrano-[3,4-b]quinoline (MF
8615), N-[8-(cis-2,6-dimethylmorpholin-4-yl)octyl]carbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester L-bitartrate hydrate (MF 268), (−
)N-(3-piperidinopropyl)-N-demethylgalantamine (SPH
1286) and N-propargyl-3R-aminoindan-5-yl-ethyl methyl carbamate (TV
3326), or a pharmaceutically acceptable salt thereof.
- ), tacrine (cognex®
Specification